ClinicalTrials.gg
Enrolling by invitationNCT07772479Updated Aug 19, 2026

Comparative Study of Rotational Cryobiopsy Needle and Automated Biopsy Needle in Transthoracic Biopsy Diagnosing Peripheral Pulmonary Lesions

An interventional study of CassiII rotational core biopsy and Automated biopsy in Peripheral Pulmonary Lesions (PPLs) and Pulmonary Nodules, sponsored by Beijing Chao Yang Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Beijing Chao Yang Hospital · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Mar 2025, registered Aug 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
308
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

This study aims to systematically compare the diagnostic efficacy, specimen quality, and complication rates of the cryobiopsy needle technique(CassiII rotational core biopsy) versus the automated biopsy technique in the biopsy of pulmonary nodules, thereby providing a reliable evidentiary basis for clinical practice.

02

Conditions studied

  • Peripheral Pulmonary Lesions (PPLs)
  • Pulmonary Nodules

Keywords

  • Rotational Cryobiopsy Needle
  • Automated Biopsy Needle
  • Diagnostic Yield
  • Peripheral Pulmonary Lesions
03

In context

Multiple Pulmonary Nodules

99 studies on the registry are indexed under Multiple Pulmonary Nodules; 42 are open to participants now.

This study's planned enrollment of 308 is above the median of 97 across 46 interventional studies indexed under Multiple Pulmonary Nodules.

Browse Multiple Pulmonary Nodules studies →

Lead sponsor

Beijing Chao Yang Hospital is the lead sponsor of 140 studies on the registry; 49 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • If a chest CT scan reveals pulmonary nodules with an unknown nature, a is required for definitive diagnosis; if the chest CT shows multiple pulmonary nodules, one of these nodules should be selected as the target lesion;

    • Axial chest CT imaging demonstrates peripheral pulmonary nodules located in the pulmonary region, with diameters ranging from 8 mm to 30 mm; ③Voluntarily undergo CT-guided lung puncture biopsy and meet all preoperative requirements; ④Participants demonstrate good compliance, are able to cooperate with the study observations, are fully informed about the study's objectives and methods, acknowledge the potential risks, agree to participate in the study, and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Severe cardiopulmonary dysfunction;

    • Irreversible coagulation disorders;

      • Suspected vascular lesions or arteriovenous malformations (assessed by contrast-enhanced CT), or presence of bronchial artery penetration at the planned site, or suspected pulmonary from renal cell carcinoma, indicating a high risk of hemorrhage;

        • PET-CT findings indicate a malignant pulmonary nodule; surgical evaluation may prioritize surgical intervention for the patient;

          • Pregnant or lactating women; ⑥ Patients with psychiatric disorders or those unable to cooperate during the puncture procedure; ⑦ Presence of anesthesia ; allergy to anesthetic agents; or a history of multiple severe allergies or hereditary allergies;

            • If the participant has participated in other studies within the past three months without withdrawing or completing those studies, this will affect the observation of the present study; ⑨ Refusal to participate in this study, unwillingness to accept the follow-up protocol, or other circumstances in which the investigator deems the participant unsuitable for participation in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
308 participants (estimated)

Study arms

  • Experimental
    CassiII rotational core biopsy group

    Under CT guidance, a percutaneous puncture is performed using a coaxial needle; upon reaching the target lesion, the CassiII rotational core biopsy needle is inserted along the coaxial needle for biopsy. At the same lesion site, ≥1 biopsy is performed; depending on sample adequacy, the maximum number of biopsies shall not exceed 3, with at least 1 tissue specimen obtained from each biopsy. Subsequently, the CassiII rotational core biopsy needle and the coaxial needle are withdrawn sequentially. After resting for 5-10 minutes, a repeat CT scan is performed to assess for any complications such as hemorrhage or pneumothorax.

    Procedure: CassiII rotational core biopsy

  • Active comparator
    Automated biopsy needle group

    Under CT guidance, a coaxial needle is percutaneously inserted; upon reaching the target lesion, an automated biopsy needle is advanced along the coaxial needle and activated. Biopsy is performed at least once at the same lesion site; depending on sample adequacy, the procedure may be repeated up to a maximum of 3 times, with at least one tissue specimen obtained from each attempt. Subsequently, the automated biopsy needle and the coaxial needle are withdrawn sequentially. After resting for 5-10 minutes, a repeat CT scan is performed to assess for any complications such as hemorrhage or pneumothorax.

    Procedure: Automated biopsy

Interventions

  • ProcedureCassiII rotational core biopsy

    CassiII rotational core biopsy needle is inserted in lesion site, ≥1 biopsy is performed.

  • ProcedureAutomated biopsy

    Automated biopsy needle is inserted in lesion site, ≥1 biopsy is performed.

06

What researchers measure

Primary outcomes

  1. Diagnostic yield of the two biopsy methods

    Diagnostic yield = (Number of pathologically positive cases / Total number of enrolled cases) × 100%

    Time frame: From enrollment to the end of procedure at 2 years

Secondary outcomes

  1. Specimen size

    biopsy tissue size (long diameter, millimeter)

    Time frame: From enrollment to the end of procedure at 2 years

  2. Consistency analysis between AI-ROSE results and pathological results

    The results of AI-ROSE were compared with the pathological results, and the consistency analysis was performed to evaluate the effectiveness of AI-ROSE

    Time frame: From enrollment to the end of procedure at 2 years

  3. Safety indicators

    Complications: Incidence (including pneumothorax, hemorrhage, respiratory failure, infection, and severe complications requiring endotracheal intubation and mechanical ventilation to be transferred to the Intensive Care Unit), severity levels, and corresponding management measures.

    Time frame: From enrollment to the end of procedure at 2 years

07

Study locations

1 site
08

References and documents

Publications

  • Xie S, Ju S, Zhang X, Qi C, Zhang J, Mao M, Chen C, Chen Y, Ji F, Zhou J, Wang L. A retrospective comparative study on the diagnostic efficacy and the complications: between CassiII rotational core biopsy and core needle biopsy. Front Oncol. 2023 Sep 26;13:1067246. doi: 10.3389/fonc.2023.1067246. eCollection 2023. PubMed 37823052 ↗
  • Yeow KM, Su IH, Pan KT, Tsay PK, Lui KW, Cheung YC, Chou AS. Risk factors of pneumothorax and bleeding: multivariate analysis of 660 CT-guided coaxial cutting needle lung biopsies. Chest. 2004 Sep;126(3):748-54. doi: 10.1378/chest.126.3.748. PubMed 15364752 ↗
  • Tai R, Dunne RM, Trotman-Dickenson B, Jacobson FL, Madan R, Kumamaru KK, Hunsaker AR. Frequency and Severity of Pulmonary Hemorrhage in Patients Undergoing Percutaneous CT-guided Transthoracic Lung Biopsy: Single-Institution Experience of 1175 Cases. Radiology. 2016 Apr;279(1):287-96. doi: 10.1148/radiol.2015150381. Epub 2015 Oct 19. PubMed 26479161 ↗
  • Vachani A, Zhou M, Ghosh S, Zhang S, Szapary P, Gaurav D, Kalsekar I. Complications After Transthoracic Needle Biopsy of Pulmonary Nodules: A Population-Level Retrospective Cohort Analysis. J Am Coll Radiol. 2022 Oct;19(10):1121-1129. doi: 10.1016/j.jacr.2022.04.010. Epub 2022 Jun 20. PubMed 35738412 ↗
  • Yoon SH, Park CM, Lee KH, Lim KY, Suh YJ, Im DJ, Hur J, Han DH, Kang MJ, Choo JY, Kim C, Kim JI, Hong H. Analysis of Complications of Percutaneous Transthoracic Needle Biopsy Using CT-Guidance Modalities In a Multicenter Cohort of 10568 Biopsies. Korean J Radiol. 2019 Feb;20(2):323-331. doi: 10.3348/kjr.2018.0064. PubMed 30672172 ↗
  • Balasubramanian P, Abia-Trujillo D, Barrios-Ruiz A, Garza-Salas A, Koratala A, Chandra NC, Yu Lee-Mateus A, Labarca G, Fernandez-Bussy S. Diagnostic yield and safety of diagnostic techniques for pulmonary lesions: systematic review, meta-analysis and network meta-analysis. Eur Respir Rev. 2024 Sep 18;33(173):240046. doi: 10.1183/16000617.0046-2024. Print 2024 Jul. PubMed 39293856 ↗
  • Tomiyama N, Yasuhara Y, Nakajima Y, Adachi S, Arai Y, Kusumoto M, Eguchi K, Kuriyama K, Sakai F, Noguchi M, Murata K, Murayama S, Mochizuki T, Mori K, Yamada K. CT-guided needle biopsy of lung lesions: a survey of severe complication based on 9783 biopsies in Japan. Eur J Radiol. 2006 Jul;59(1):60-4. doi: 10.1016/j.ejrad.2006.02.001. Epub 2006 Mar 10. PubMed 16530369 ↗
  • Wiener RS, Schwartz LM, Woloshin S, Welch HG. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med. 2011 Aug 2;155(3):137-44. doi: 10.7326/0003-4819-155-3-201108020-00003. PubMed 21810706 ↗
  • Heerink WJ, de Bock GH, de Jonge GJ, Groen HJ, Vliegenthart R, Oudkerk M. Complication rates of CT-guided transthoracic lung biopsy: meta-analysis. Eur Radiol. 2017 Jan;27(1):138-148. doi: 10.1007/s00330-016-4357-8. Epub 2016 Apr 23. PubMed 27108299 ↗
  • Huo YR, Chan MV, Habib AR, Lui I, Ridley L. Pneumothorax rates in CT-Guided lung biopsies: a comprehensive systematic review and meta-analysis of risk factors. Br J Radiol. 2020 Apr 1;93(1108):20190866. doi: 10.1259/bjr.20190866. Epub 2020 Jan 3. PubMed 31860329 ↗
  • Tachibana K, Nakazato Y, Tsuchida S, Kazama T, Minato K, Yoshida T, Fujita A, Horikoshi H, Tanaka R, Iijima M, Goya T. Immediate cytology improves accuracy and decreases complication rate in real-time computed tomography-guided needle lung biopsy. Diagn Cytopathol. 2013 Dec;41(12):1063-8. doi: 10.1002/dc.22940. Epub 2012 Dec 14. PubMed 23239643 ↗
  • Yamagami T, Yoshimatsu R, Miura H, Yamada K, Takahata A, Matsumoto T, Hasebe T. Diagnostic performance of percutaneous lung biopsy using automated biopsy needles under CT-fluoroscopic guidance for ground-glass opacity lesions. Br J Radiol. 2013 Feb;86(1022):20120447. doi: 10.1259/bjr.20120447. PubMed 23385998 ↗
  • Zhang L, Shi L, Xiao Z, Qiu H, Peng P, Zhang M. Coaxial technique-promoted diagnostic accuracy of CT-guided percutaneous cutting needle biopsy for small and deep lung lesions. PLoS One. 2018 Feb 15;13(2):e0192920. doi: 10.1371/journal.pone.0192920. eCollection 2018. PubMed 29447239 ↗
  • Kothary N, Lock L, Sze DY, Hofmann LV. Computed tomography-guided percutaneous needle biopsy of pulmonary nodules: impact of nodule size on diagnostic accuracy. Clin Lung Cancer. 2009 Sep;10(5):360-3. doi: 10.3816/CLC.2009.n.049. PubMed 19808195 ↗
  • Yeow KM, Tsay PK, Cheung YC, Lui KW, Pan KT, Chou AS. Factors affecting diagnostic accuracy of CT-guided coaxial cutting needle lung biopsy: retrospective analysis of 631 procedures. J Vasc Interv Radiol. 2003 May;14(5):581-8. doi: 10.1097/01.rvi.0000071087.76348.c7. PubMed 12761311 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07772479
Responsible party
Sponsor
First posted
Aug 19, 2026
Start date
Mar 1, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Aug 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion